GlaxoSmithKline Spotlights Immune System And Oncology R&D
Two-Year Effort To Refocus Research Pipeline Bearing Fruit
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.
